“…The sole identification of the MYD88 L265P mutation in the CSF, however, is not diagnostic for BNS, because this mutation can also be detected in a substantial proportion of patients with primary CNS lymphoma (Montesinos-Rongen et al, 2011;Gonzalez-Aguilar et al, 2012;Nakamura et al, 2016). The MYD88 L265P mutation can also be detected in a minority of patients with chronic lymphocytic leukaemia (CLL) or marginal zone lymphoma (MZL) and low-grade lymphoproliferative disorders, in which CNS involvement can also rarely develop (Jesionek-Kupnicka et al, 2013;Ueba et al, 2013;Rossi et al, 2014;Strati et al, 2016;Wanquet et al, 2016;Ayanambakkam et al, 2018).…”